MOUNTAIN VIEW, CALIFORNIA, February 13, 2013 – Based on its recent analysis of the global biosensors market, Frost & Sullivan recognized Sensor-Kinesis’ (SKC) parent company Pharmaco-Kinesis Corporation (PKC) with the 2013 Global Frost & Sullivan Award for New Product Innovation. The company has set a new standard in the biosensors market with its innovative, highly sensitive biosensor. This unique, multi-pathogen detection device utilizes electrochemical impedance spectroscopy (EIS) to detect pathogens such as E.coli 0157:H7 and the severe acute respiratory syndrome (SARS) virus. It offers higher sensitivity , accuracy, cost–savings. Other key advantages are its greater portability and reusability; and a shorter, less complex testing process than other biosensors in the market.
SKC’s biosensor sample preparation is conducted in a controlled environment, which eliminates the possibility of contamination. Additionally, SKC biosensors require minimal human intervention and provide immediate, real-time pathogen detection. The product has a longer lifespan than similar solutions and can operate efficiently for more than five years with repeated use.
Unlike other pathogen test instruments that utilize test strips or incubators, SKC biosensors use a biosensor container with an electrochemical sensor attached to the base, along with a liquid mixer and a microprocessor that records biosensor readings. This entire device is encased in protective housing, which includes a container holder. This technology lets the pathogen detection status be obtained remotely in real time using radio frequency identification (RFID) readers.
“This new biosensor offers a number of advantages over the other pathogen test solutions in the market. For example, the lateral flow method requires about eight hours for sample preparation and testing, while SKC’s new technology takes only four hours,” said Frost & Sullivan Research Analyst Dr. Rajender Thusu. “Further, this technology can detect E.coli 0157:H7, even when it is present in colonies of hundreds, a considerably smaller population than required by other test methods.”
Additionally, SKC’s technology requires only a consumable input of only bacteria culture medium, which makes this solution highly cost-effective. Using a vertical orientation of colonies, instead of existing test solutions’ horizontal orientation, significantly accelerates the detection process.
As SKC’s biosensors also offer automated signal generation and high ease of use, it does away with the need to train technicians or use expensive additional equipment. The SKC test instrument requires only an initial investment, instead of the recurring investments needed by other test solutions. Overall, SKC lowers the cost of pathogen testing to almost half of that of lateral-flow technology.
“Although designed for use across a number of application areas, SKC’s biosensors are used primarily in food processing,” noted Dr.Thusu. “They also demonstrate high growth potential in the application areas of patient care monitoring, biodefense, environmental monitoring, and infection control. Another key application area detection of biomarkers related to all cancer types, genetic makers, DAN, RNA and CNS battery of diseases including Alzheimer’s biomarkers, Parkinson and MS.”
SKC’s constant focus on tracking emerging customer needs enables it to introduce industry-first products and solutions designed to offer high customer value and increased return on investment (ROI). SKC is also developing biosensors using nanotechnology, including nanobiosensors, for both in-vivo and in-vitro monitoring of biomarker levels.
Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which, in turn, increases customer acquisition and overall market penetration potential.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry
Announcement of this award and the significance of PKC’s and SKC’s accomplishments has quickly spread across major media outlets sparking nationwide and even global interest in the company’s mission and its technology.
Sensor-Kinesis Corp. is the manufacturer and developer of an advanced biosensor micro-chip technology that has created a paradigm shift in the ability to detect air- and food-borne pathogens, infectious diseases and early-stage cancers faster, more accurately and with substantially lower cost than has ever been possible before. As a result, Sensor-Kinesis’ proprietary innovations allow physicians, health and safety organizations and individuals an ability to detect diseases and other detractors to our health and well-being at the earliest stage possible.
This news release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements are based upon the current beliefs and expectations of the management of Sensor-Kinesis Corporation and are subject to significant risks and uncertainties. Actual results may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
For additional information on any of the press releases shown here, please contact: